newsfilter
← Latest News
GlobeNewswire·

Constellation Pharmaceuticals Presents Phase 1 Data for CPI-0209 at ASCO Annual Meeting

Pharmacodynamic data show comprehensive target engagement after treatment with CPI-0209 monotherapy Oral, once-daily 350mg dose selected for Phase 2 Enrollment of tumor-specific expansion cohorts is ongoing CAMBRIDGE, Mass., June 04, 2021 (GLO